SLNO Soleno Therapeutics Inc

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.

A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at .

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit .

Corporate Contact:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578



EN
27/11/2024

Underlying

SLNOSoleno Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Soleno Therapeutics Inc

 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Pricing of $200 Million Public Offering ...

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an ad...

July 10, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Proposed $200 Million Public Offering of...

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. The proposed public offering is subject ...

July 10, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Preliminary Financial and Operational Re...

Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025: Soleno expects its net revenue from the sales of VYKATTM XR, for the three months ended June 30, 2025 to be between $31.0 million and $33.0 million....

July 10, 2025 1 EN
Free Trial
SLNO Soleno Therapeu...

Soleno Therapeutics Inc: 1 director

A director at Soleno Therapeutics Inc sold 3,830 shares at 82.760USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

SLNO SOLENO THERAPEUTICS INC
07/04/25 July 4, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR...

Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 REDWOOD CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that two abstracts featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets, previously known as DCCR, have been selected for presentation at the Annual Meeting of the Endocrine Society (ENDO 2025), which is being held July 12-15, 2025, in San Francisco...

July 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch